• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

底物质子化和互变异构态对精氨酸酶 I 活性部位相互作用的影响。

Impact of substrate protonation and tautomerization states on interactions with the active site of arginase I.

机构信息

Department of Pharmaceutical Sciences, University of Maryland, School of Pharmacy, 20 Penn Street HSFII, Baltimore, Maryland 21201, USA.

出版信息

J Chem Inf Model. 2013 Feb 25;53(2):452-60. doi: 10.1021/ci300506y. Epub 2013 Jan 31.

DOI:10.1021/ci300506y
PMID:23327293
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3590304/
Abstract

Human arginase is a binuclear manganese metalloenzyme that participates in the urea cycle. Arginase catalyzes the hydrolysis of L-arginine into L-ornithine and urea and is linked to several disorders such as asthma and cancer. Currently, the protonation and tautomerization state of the substrate when bound to the active site, which contains two manganese ions, is not known. Knowledge of the charge-dependent behavior of arginine in the arginase I environment would be of utility toward understanding the catalytic mechanism and designing inhibitors of this enzyme. The arginine(+/0) species, including all possible neutral tautomers, were modeled using an aminoimidazole analog as template. All-atom molecular dynamics simulations were then performed on each of the charged and neutral species. In addition, a hydroxide ion was included in selected simulations to test its importance. Results show that the positively charged state of arginine is stable in the active site of arginase I, with that stabilization facilitated by the presence of hydroxide. Glu277 is indicated to play a role in stabilizing arginine in the active site and facilitating its ability to assume a catalytically competent conformation in the presence of hydroxide. The reported interactions and modeled arginine-bound arginase I structures can be used as a tool for structure-based inhibitor design, as experimental data on the structure of the substrate-enzyme complex is lacking.

摘要

人精氨酸酶是一种双核锰金属酶,参与尿素循环。精氨酸酶催化 L-精氨酸水解为 L-鸟氨酸和尿素,并与哮喘和癌症等几种疾病有关。目前,与包含两个锰离子的活性位点结合的底物的质子化和互变异构状态尚不清楚。了解精氨酸酶 I 环境中精氨酸的电荷依赖性行为对于理解催化机制和设计该酶的抑制剂将是有用的。使用氨基咪唑类似物作为模板对精氨酸(+/0)物种,包括所有可能的中性互变异构体进行建模。然后对每个带电和中性物种进行全原子分子动力学模拟。此外,在选定的模拟中还包括了一个氢氧根离子,以测试其重要性。结果表明,带正电荷的精氨酸在精氨酸酶 I 的活性部位稳定存在,氢氧根的存在促进了其稳定。Glu277 被表明在稳定精氨酸在活性部位和促进其在氢氧根存在下能够假设催化活性构象方面发挥作用。所报道的相互作用和模拟的精氨酸结合的精氨酸酶 I 结构可作为基于结构的抑制剂设计的工具,因为缺乏关于底物-酶复合物结构的实验数据。

相似文献

1
Impact of substrate protonation and tautomerization states on interactions with the active site of arginase I.底物质子化和互变异构态对精氨酸酶 I 活性部位相互作用的影响。
J Chem Inf Model. 2013 Feb 25;53(2):452-60. doi: 10.1021/ci300506y. Epub 2013 Jan 31.
2
L-arginine binding to liver arginase requires proton transfer to gateway residue His141 and coordination of the guanidinium group to the dimanganese(II,II) center.L-精氨酸与肝脏精氨酸酶的结合需要质子转移至门户残基His141,并使胍基与二锰(II,II)中心配位。
Biochemistry. 1998 Jun 9;37(23):8539-50. doi: 10.1021/bi972874c.
3
Crystal structures of Bacillus caldovelox arginase in complex with substrate and inhibitors reveal new insights into activation, inhibition and catalysis in the arginase superfamily.嗜热栖热芽孢杆菌精氨酸酶与底物及抑制剂复合物的晶体结构揭示了精氨酸酶超家族中激活、抑制和催化作用的新见解。
Structure. 1999 Apr 15;7(4):435-48. doi: 10.1016/s0969-2126(99)80056-2.
4
Inhibitor coordination interactions in the binuclear manganese cluster of arginase.精氨酸酶双核锰簇中的抑制剂配位相互作用。
Biochemistry. 2004 Jul 20;43(28):8987-99. doi: 10.1021/bi0491705.
5
Mechanistic and metabolic inferences from the binding of substrate analogues and products to arginase.基于底物类似物和产物与精氨酸酶结合的机制及代谢推断
Biochemistry. 2001 Mar 6;40(9):2689-701. doi: 10.1021/bi002318+.
6
Binding of the unreactive substrate analog L-2-amino-3-guanidinopropionic acid (dinor-L-arginine) to human arginase I.无反应性底物类似物L-2-氨基-3-胍基丙酸(二去甲-L-精氨酸)与人精氨酸酶I的结合。
Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012 Aug 1;68(Pt 8):889-93. doi: 10.1107/S1744309112027820. Epub 2012 Jul 27.
7
Inhibition of human arginase I by substrate and product analogues.人精氨酸酶 I 的底物和产物类似物的抑制作用。
Arch Biochem Biophys. 2010 Apr 15;496(2):101-8. doi: 10.1016/j.abb.2010.02.004. Epub 2010 Feb 12.
8
Structure of a unique binuclear manganese cluster in arginase.精氨酸酶中独特双核锰簇的结构
Nature. 1996 Oct 10;383(6600):554-7. doi: 10.1038/383554a0.
9
Metal-induced change in catalytic loop positioning in Helicobacter pylori arginase alters catalytic function.金属诱导幽门螺杆菌精氨酸酶催化环定位改变,从而改变其催化功能。
Biochem J. 2019 Dec 12;476(23):3595-3614. doi: 10.1042/BCJ20190545.
10
Catalytic mechanism of DcsB: Arginase framework used for hydrolyzing its inhibitor.DcsB 的催化机制:精氨酸酶骨架用于水解其抑制剂。
Protein Sci. 2022 Jun;31(6):e4338. doi: 10.1002/pro.4338.

引用本文的文献

1
QM/MM Simulations for the Broken-Symmetry Catalytic Reaction Mechanism of Human Arginase I.人精氨酸酶I破缺对称性催化反应机制的量子力学/分子力学模拟
ACS Omega. 2022 Aug 30;7(36):32536-32548. doi: 10.1021/acsomega.2c04116. eCollection 2022 Sep 13.
2
Virtual Screening for FDA-Approved Drugs That Selectively Inhibit Arginase Type 1 and 2.虚拟筛选选择性抑制精氨酸酶 1 型和 2 型的 FDA 批准药物。
Molecules. 2022 Aug 12;27(16):5134. doi: 10.3390/molecules27165134.
3
Mapping the Molecular Architecture Required for Lipid-Binding Pockets Using a Subset of Established and Orphan G-Protein Coupled Receptors.利用一组已确立的和孤儿G蛋白偶联受体绘制脂质结合口袋所需的分子结构。
J Chem Inf Model. 2021 Jul 26;61(7):3442-3452. doi: 10.1021/acs.jcim.1c00335. Epub 2021 Jul 9.
4
Arginase as a Potential Biomarker of Disease Progression: A Molecular Imaging Perspective.精氨酸酶作为疾病进展的潜在生物标志物:分子影像学视角。
Int J Mol Sci. 2020 Jul 25;21(15):5291. doi: 10.3390/ijms21155291.

本文引用的文献

1
Arginase inhibitor in the pharmacological correction of endothelial dysfunction.精氨酸酶抑制剂在血管内皮功能障碍的药理纠正中的应用
Int J Hypertens. 2011;2011:515047. doi: 10.4061/2011/515047. Epub 2011 Jun 15.
2
Arginase and arginine dysregulation in asthma.哮喘中的精氨酸酶与精氨酸失调
J Allergy (Cairo). 2011;2011:736319. doi: 10.1155/2011/736319. Epub 2011 Apr 26.
3
Arginase-1-expressing macrophages are dispensable for resistance to infection with the gastrointestinal helminth Trichuris muris.表达精氨酸酶-1 的巨噬细胞对于抵抗胃肠道寄生虫旋毛虫感染是可有可无的。
Parasite Immunol. 2011 Jul;33(7):411-20. doi: 10.1111/j.1365-3024.2011.01300.x.
4
Modeling gas phase nitric oxide release in lung epithelial cells.模拟肺上皮细胞中气相一氧化氮的释放。
Nitric Oxide. 2011 Oct 30;25(3):275-81. doi: 10.1016/j.niox.2011.04.010. Epub 2011 Apr 30.
5
Crystal structure of arginase from Plasmodium falciparum and implications for L-arginine depletion in malarial infection .恶性疟原虫精氨酸酶的晶体结构及其在疟原虫感染中 L-精氨酸耗竭的意义。
Biochemistry. 2010 Jul 6;49(26):5600-8. doi: 10.1021/bi100390z.
6
2-aminoimidazole amino acids as inhibitors of the binuclear manganese metalloenzyme human arginase I.2-氨基咪唑氨基酸作为双锰金属酶人精氨酸酶 I 的抑制剂。
J Med Chem. 2010 May 27;53(10):4266-76. doi: 10.1021/jm100306a.
7
Cardiovascular effects of arginase inhibition in spontaneously hypertensive rats with fully developed hypertension.在已发展为完全期高血压的自发性高血压大鼠中,精氨酸酶抑制对心血管的影响。
Cardiovasc Res. 2010 Aug 1;87(3):569-77. doi: 10.1093/cvr/cvq081. Epub 2010 Mar 10.
8
Inhibition of human arginase I by substrate and product analogues.人精氨酸酶 I 的底物和产物类似物的抑制作用。
Arch Biochem Biophys. 2010 Apr 15;496(2):101-8. doi: 10.1016/j.abb.2010.02.004. Epub 2010 Feb 12.
9
Arginase: a key enzyme in the pathophysiology of allergic asthma opening novel therapeutic perspectives.精氨酸酶:变应性哮喘病理生理学中的关键酶,开辟了新的治疗前景。
Br J Pharmacol. 2009 Oct;158(3):652-64. doi: 10.1111/j.1476-5381.2009.00374.x. Epub 2009 Aug 24.
10
CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields.CHARMM 通用力场:适用于 CHARMM 全原子加和生物力场的药物样分子力场。
J Comput Chem. 2010 Mar;31(4):671-90. doi: 10.1002/jcc.21367.